Istituto Superiore di Sanita Patent applications |
Patent application number | Title | Published |
20140193445 | Truncated Secretory Aspartyl Proteinase 2 - The present invention relates to an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. The present invention also relates to a composition comprising an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. | 07-10-2014 |
20120321615 | Assay for Metastatic Colorectal Cancer - Disclosed herein is a method for predicting the prognosis, the likelihood of metastasis in, or the desirability of administering an aggressive therapy to, a subject with colorectal cancer, comprising determining, in a sample from the subject, the level of phosphorylation of one or more of certain proteins compared to a positive and/or negative reference standard; or the total amount of COX-2 protein compared to a positive and/or negative reference standard. Also described are methods for treating subjects likely to develop metastatic colorectal carcinoma, and pharmaceutical compositions and kits for implementing the methods of the invention. | 12-20-2012 |
20110305774 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS - Activation of HIV-1 replication causes oxidative stress, which in turn potentiates HIV-1 replication. The common basis for the compounds of the present invention is: A) the capacity of reactivating HIV-1 from latency, and B) the ability to counteract the cellular machinery which activates in order to limit the effects of oxidative stress. In this way, oxidative stress can be potentiated and a “chain reaction” is sparked. This “chain reaction” induces a more efficient reactivation of HIV-1 from latency and, in some cases, induces selective killing of the infected cells. Actions A) and B) can either be carried out by one drug exerting both effects, or obtained by the combined use of distinct drugs. There are two main cellular machineries counteracting oxidative stress, i.e. the thioredoxin (Trx) thioredoxin reductase (TrxR) system and glutathione. Herein, we present drug strategies capable of exerting action B) by blocking either of the two machineries. | 12-15-2011 |
20110123499 | CELLULAR DIFFERENTIATION PROMOTION - Neural precursor cells can be encouraged to form mature neural cells twice as quickly in the absence, or reduced expression of, thymosin β4. | 05-26-2011 |
20100285109 | TRUNCATED SECRETORY ASPARTYL PROTEINASE 2 - The present invention relates to a truncated form of the secretory aspartyl proteinase 2 (Sap2), as well as to nucleic acid molecules encoding same. This truncated Sap2 polypeptide (tSap2) is surprisingly stable and devoid of enzymatic activity but retains full immunogenicity upon intravaginal administration and confers full protection against intravaginal challenge by the | 11-11-2010 |
20100143949 | BIOMARKERS FOR COLORECTAL CANCER - Low molecular weight (LMW) peptides have been discovered that are indicative of colorectal cancer. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting colorectal cancer and monitoring the progression of the disease. The LMW peptides are particularly useful in detecting colorectal cancer during its early stages. | 06-10-2010 |
20100024049 | Digestive System Cancer Stem Cells and Tests and Uses Therefor - The CD133 marker has been found to be diagnostic of tumourigenic digestive system cancer, particularly malignant colorectal cancers. Tests to show such cells and uses for such cells are disclosed. | 01-28-2010 |
20100016406 | Antisense RNA for Treating Cancer and Inhibition of Metastasis and Vectors for Antisense Sequestration - Provided is the use of antisense RNA and methods for the treatment, diagnosis and prophylaxis of cancer comprising administering said antisense RNA, particularly miRs 15 and 16 to a patient in need thereof. | 01-21-2010 |
20090275546 | Diagnostic tests and personalized treatment regimes for cancer stem cells - Provided are methods of identifying a metabolic target in a cancer stem cell that include using a microarray to identify intracellular signaling networks within a population of cancer stem cells that respond to a growth factor for the stem cell. Also provided are methods of determining a personalized therapeutic regime that include receiving metabolic information relating to a cancer stem cell in a patient, determining the patient's personal criteria relevant to the therapeutic regime, and combining the metabolic and personal criteria. Also provided are a diagnostic test for establishing a personalized therapeutic regime for a colon cancer patient and methods of reducing colon cancer stem cells/treating colon cancer. | 11-05-2009 |
20090203892 | Retrotransposon Inhibition in Therapy - RNA interference is useful in the treatment of cancerous lesions, wherein the RNA recognises a portion of at least one LINE-I repeat element. | 08-13-2009 |
20090081196 | Medicaments for fungal infections - The protein CAMP65p of | 03-26-2009 |
20090041792 | Dendritic cells, uses therefor, and vaccines and methods comprising the same - Provided is a method of cross-priming CD8+ T cells to antigens using Dendritic Cells cultured in the presence of a type I Interferon and GM-CSF, and vaccines and methods of vaccination comprising said Dendritic Cells. | 02-12-2009 |
20080254488 | Cancer Test - The CD133 marker has been found to be diagnostic of malignant lung cancers. Tests and kits to show such cells and uses for such cells are disclosed. | 10-16-2008 |